Literature DB >> 2147047

Activation of leukemic large granular lymphocytes by interleukin-2 via the p75 interleukin-2 receptor.

H J Yoon1, K Sugamura, T P Loughran.   

Abstract

We studied the role of interleukin-2 (IL-2) receptor subunits in the activation of leukemic CD3+ large granular lymphocytes (LGL). Peripheral blood mononuclear cells from four patients with CD3+ LGL leukemia were activated with 500 mu/ml of recombinant IL-2. Induction of both proliferative and cytotoxic functions by IL-2 was blocked by addition of anti-p75 IL-2 receptor monoclonal antibody, but not by addition of anti-p55 IL-2 receptor monoclonal antibody. Sorting experiments demonstrated directly that the effects of the anti-p75 IL-2 receptor monoclonal antibody were on leukemic LGL. These results show constitutive expression of functional p75 IL-2 receptors on leukemic LGL and suggest a possible mechanism for leukemic LGL proliferation in vivo.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2147047

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  3 in total

1.  Antigen activation and impaired Fas-induced death-inducing signaling complex formation in T-large-granular lymphocyte leukemia.

Authors:  Jun Yang; P K Epling-Burnette; Jeffrey S Painter; Jianxiang Zou; Fanqi Bai; Sheng Wei; Thomas P Loughran
Journal:  Blood       Date:  2007-11-09       Impact factor: 22.113

2.  Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression.

Authors:  P K Epling-Burnette; J H Liu; R Catlett-Falcone; J Turkson; M Oshiro; R Kothapalli; Y Li; J M Wang; H F Yang-Yen; J Karras; R Jove; T P Loughran
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

Review 3.  Neutropenia and Large Granular Lymphocyte Leukemia: From Pathogenesis to Therapeutic Options.

Authors:  Giulia Calabretto; Antonella Teramo; Gregorio Barilà; Cristina Vicenzetto; Vanessa Rebecca Gasparini; Gianpietro Semenzato; Renato Zambello
Journal:  Cells       Date:  2021-10-19       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.